1. Home
  2. EOI vs AKBA Comparison

EOI vs AKBA Comparison

Compare EOI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

EOI

Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

N/A

Current Price

$19.52

Market Cap

805.7M

Sector

Finance

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$1.32

Market Cap

729.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EOI
AKBA
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
805.7M
729.1M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
EOI
AKBA
Price
$19.52
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$5.75
AVG Volume (30 Days)
69.3K
3.4M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.84
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.50
$1.14
52 Week High
$21.58
$4.08

Technical Indicators

Market Signals
Indicator
EOI
AKBA
Relative Strength Index (RSI) 28.30 50.75
Support Level $19.34 $1.30
Resistance Level $20.90 $1.55
Average True Range (ATR) 0.23 0.07
MACD -0.08 0.01
Stochastic Oscillator 7.15 48.65

Price Performance

Historical Comparison
EOI
AKBA

About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: